Stearic Acid-g-chitosan Polymeric Micelle for Oral Drug Delivery: In Vitro Transport and in Vivo Absorption

2010 ◽  
Vol 8 (1) ◽  
pp. 225-238 ◽  
Author(s):  
Hong Yuan ◽  
Lin-Juan Lu ◽  
Yong-Zhong Du ◽  
Fu-Qiang Hu
Pharmaceutics ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 416 ◽  
Author(s):  
Schneider ◽  
Koziolek ◽  
Weitschies

More than 50 years ago, the first concepts for gastroretentive drug delivery systems were developed. Despite extensive research in this field, there is no single formulation concept for which reliable gastroretention has been demonstrated under different prandial conditions. Thus, gastroretention remains the holy grail of oral drug delivery. One of the major reasons for the various setbacks in this field is the lack of predictive in vitro and in vivo test methods used during preclinical development. In most cases, human gastrointestinal physiology is not properly considered, which leads to the application of inappropriate in vitro and animal models. Moreover, conditions in the stomach are often not fully understood. Important aspects such as the kinetics of fluid volumes, gastric pH or mechanical stresses have to be considered in a realistic manner, otherwise, the gastroretentive potential as well as drug release of novel formulations cannot be assessed correctly in preclinical studies. This review, therefore, highlights the most important aspects of human gastrointestinal physiology and discusses their potential implications for the evaluation of gastroretentive drug delivery systems.


1992 ◽  
Vol 19 (1-3) ◽  
pp. 131-144 ◽  
Author(s):  
Waleed S.W. Shalaby ◽  
William E. Blevins ◽  
Kinam Park

2017 ◽  
Vol 14 (3) ◽  
pp. 757-769 ◽  
Author(s):  
Mohammed S. Alqahtani ◽  
M. Saiful Islam ◽  
Satheesh Podaralla ◽  
Radhey S. Kaushik ◽  
Joshua Reineke ◽  
...  

2006 ◽  
Vol 6 (9) ◽  
pp. 3203-3209 ◽  
Author(s):  
Hesham H. Salman ◽  
Carlos Gamazo ◽  
Miguel A. Campanero ◽  
Juan M. Irache

The aim of this work was to design mannosylated Gantrez® AN nanoparticles (M-NP) and to describe their gut bioadhesive properties in order to develop a promising carrier for future applications in oral drug delivery. For that purpose, the process of the nanoparticles coating with mannosamine was optimized by the incubation of Gantrez® AN nanoparticles with different volumes of mannosamine aqueous solutions at different times. Then, the nanoparticles were characterized by measuring the size, zeta potential, mannosamine content, and concanavalin A (Con A) binding. Furthermore, in vivo quantitative bioadhesion study and kinetic analysis of the bioadhesion curves were performed after oral administration to rats of fluorescently labelled nanoparticles. The selected mannosylated nanoparticles (M-NP1 and M-NP10) were of homogenous sizes (about 300 and 200 nm), negatively charged and successfully coated with 36 and 18 μg mannosamine/mg NP, respectively. In vitro agglutination assay using Con A confirmed the successful coating of nanoparticles with mannosamine. The gut distribution profile of M-NP1 indicated a stronger bioadhesive capacity than M-NP10 and non-mannosylated ones, 1 h post-administration. Interestingly, M-NP1 showed an important ileum tropism where around 20% of the given dose remained adhered. Besides, the kinetic parameters of the bioadhesion profile of M-NP1 indicated their higher bioadhesive capacity with Qmax and AUCadh about 2-times higher than control ones. Moreover, fluorescence microscopy corroborated the stronger interactions of M-NP1 with the normal mucosa and demonstrated a strong uptake of these carriers by Peyer's patches. In conclusion, we propose that mannosylated nanoparticles could be a promising non-live vector for oral delivery strategies.


Author(s):  
Archana Tomar ◽  
Arpita Singh ◽  
Amresh Gupta ◽  
Satyawan Singh

The main motto of working on that article on floating drug delivery systems (FDDS) is to make a compiled report on the recent studies and research with special consideration on the principle mechanism of flotation to achieve gastric retention. The scientific and technological advancements were made in the last few years in the research and development of rate-controlled oral drug delivery systems by overcoming physiological difficulties, like short gastric residence times (GRT) and unpredictable gastric emptying times (GET). This review also epitomized the in-vitro procedure, in-vivo to assess the pursuance and implementation of floating systems, and applications of these systems. These methods are useful to various queries experienced during the development of a pharmaceutical dosage form.


2015 ◽  
Vol 14 (1) ◽  
pp. 17-27 ◽  
Author(s):  
MA Momoh ◽  
FC Kenechukwu ◽  
MS Gwarzo ◽  
PF Builders

Ibuprofen (IBU) is an anti-inflammatory drug characterized by low solubility and bioavailabilty. This study was to develop IBU-liposphere and investigated for in vitro and in vivo performance. IBU free base was incorporated into lipospheres based on micronized beeswax and Phospholipon® 90H in the ratio of (1:3), via hot emulsification. IBU-loaded lipospheres were characterized based on morphology, encapsulation efficiency (EE%), and in vitro drug release. Analgesic, anti-inflammatory activities and the pharmacokinetics were similarly evaluated. Minimum and maximum encapsulation efficiency (EE%) of 89.4 and 97.9% were obtained for lipospheres A1 and A3, respectively. Stable, spherical and smooth lipospheres of size range 101 ± 0.30 to 178 ± 0.30 ?m were obtained. Minimum and maximum release of 75 and 96.9% were obtained for A1 and A3, respectively. Significant (p<0.005) analgesic and anti-inflammatory activities were achieved with prolong plasma concentration. IBU-lipospheres based on beeswax and phospholipid could be explored as an alternative drug delivery system.Dhaka Univ. J. Pharm. Sci. 14(1): 17-27, 2015 (June)


Sign in / Sign up

Export Citation Format

Share Document